Ketamine Is Still a Medicine. A Manchester Detox Ward Shows What Happens When It Stops Being One.

In a specialist detox unit in Greater Manchester, the average person admitted for ketamine started using at 18, has been at it a little over five years, and takes about 5.4 grams a day, mostly inhaled. Three clinicians at that unit counted 59 such admissions between January 2016 and September 2025, and roughly a third of them walked in during the first eight months of 2025. Anxiety, depression, suicidal thoughts and past suicide attempts were common. So were bladder damage, kidney swelling and injury to the nose. When the drug stopped, the two things patients felt most were craving and anxiety.

Ketamine did not change. What changed is that nobody is standing between the dose and the person.

That sentence is the whole story, and it cuts two ways. Ketamine is a real medicine for people whose depression has not moved for anything else, and the US now has a nasal-spray version, esketamine, cleared by the FDA in January 2025 to be used on its own. It is also a dissociative, a drug that detaches you from your body and your surroundings, and the same detachment that can feel like relief from a mind you cannot stand is the thing a brain learns to reach for again.

The harm lives where the supervision ends

If you want to know whether ketamine is “addictive,” the honest answer depends on the room. A 2026 systematic review in the Journal of Psychopharmacology by Shreya Vasudeva, Roger McIntyre, Joshua Rosenblat and colleagues looked at abuse liability in people treated for mood disorders and found little evidence of misuse or dependence when the treatment was medically supervised. Where misuse did show up, it clustered around dosing outside a structured protocol: taking more, or more often, than a clinic would give.

That is the finding the ketamine industry quotes, and it is real. It is also a finding about a controlled room. The US esketamine product, Spravato, is dispensed only through a safety program that requires certified settings and observation after the dose. Most of what is now sold as “ketamine therapy” lives outside that fence. Psychiatrist Mark Gold, writing in Psychology Today on August 3, cited a 2026 study of 233 clinics advertising ketamine treatment in the New York metro area: more than a third advertised at-home treatment, and only 51.5 percent listed a physician on the team. Gold’s own line for why that matters is short: “The brain learns what it repeats.”

The gap between the clinic and the street is also a gap in the law. Ketamine has been sold in the US since the 1970s as an injectable anesthetic, and the DEA moved it to Schedule III, the tier for drugs with accepted medical use and a moderate-to-low dependence potential, in 1999. A clinician can prescribe a Schedule III drug. What that clinician must do first, and whether anyone checks, varies by state and by license type. On June 23, the FDA sent warning letters to online sellers of unapproved ketamine, including sites selling lozenges and powder to US customers with no clinician involved at all. A federal approval for one nasal spray is not a license for everything with the same name on the label.

What the UK numbers can and cannot tell an American

The UK has counted this longer than we have. England’s Advisory Council on the Misuse of Drugs, in its January 2026 review, reported that last-year ketamine use among adults 16 to 59 in England and Wales rose from about 160,000 people in 2014-15 to a peak near 299,000 in 2022-23, then eased to about 264,000. Most people who use it never get into trouble. The Council estimated that 5 to 8 percent develop frequent, high-dose use. Among those who do, roughly 10 percent of regular users show liver and bile-duct injury, and more than a quarter report chronic abdominal pain. People entering UK drug treatment with ketamine as the problem drug rose about twelvefold over the decade.

Among those who do, roughly 10 percent of regular users show liver and bile-duct injury, and more than a quarter report chronic abdominal pain.

Here is what those numbers do not say. The Manchester paper covers one unit and 59 people, built by looking back through records, and it is available only as an abstract that its listing says was reviewed by the Royal College of Psychiatrists’ academic faculty rather than through standard peer review. The ACMD figures are a UK household survey and a UK treatment system. Neither tells you the US rate. We do not have a clean US equivalent, and the number that briefly filled that gap turned out to be wrong: the National Drug Early Warning System reported in July that EMS crews logged 71,924 suspected ketamine overdose encounters from 2023 to mid-2026, then corrected it in August to 10,783 after finding its search had counted EMS crews giving ketamine as treatment. The corrected trend still points up, statistically significantly. Some outlets are still repeating the old figure, so check the date before you share it.

We have watched this film before. Ketamine started as a hospital anesthetic in 1970. By the late 1990s it was “Special K” on dance floors, and in 1999 Washington scheduled it as a controlled substance. Then researchers noticed that a low dose could lift severe depression within hours, and the same compound became a medicine again, wrapped in a clinic, a waiting room and a price tag. Each turn of that wheel treated the drug as the thing that changed. The people were always the same: some looking for relief, some looking for escape, and a few who could not tell, at 2 a.m., which one they were doing. The ACMD’s answer this year was telling. It considered moving ketamine to Class A, the strictest UK tier, and said no, concluding that reclassification alone would be unlikely to reduce harms and could deter people from asking for help.

Why relief can turn into the reason you come back

If you have ever used ketamine to get through a bad winter and wondered why the thing that helped started asking for more, nothing is wrong with your character. Relief is the most reinforcing thing a brain can receive. A drug that quiets a mind that has been loud for years teaches the brain, quickly and thoroughly, that this is the door. Psychologists call that learning reinforcement. You can call it the brain keeping score. In Manchester, anxiety, depression and suicidal thoughts were common among the patients, and the ones using several drugs at once had more post-traumatic stress.

That is also why the cravings and anxiety of withdrawal matter more than the physical symptoms. Taking the drug away removes the relief and leaves the original problem, now louder. The Manchester unit used a diazepam tapering regimen and most patients completed detox, which is worth saying plainly: stopping is survivable, and the ACMD notes that some effects can improve after stopping, even if bladder and liver damage can be permanent. What remains thin is the treatment that comes after. A 2026 systematic review of medical treatments for ketamine misuse found the evidence for any of them weak and called for controlled studies. Nobody can currently hand a patient a ketamine equivalent of buprenorphine.

What to do this week

If you work in treatment, add one question to your intake: “Have you used ketamine, in a clinic or on your own?” Then add two symptom questions most intake forms skip: bladder pain, urgency or blood when you pee, and unexplained abdominal pain. Both are on the damage list above, and neither is something a patient connects to a drug they think of as a depression treatment. If a client is in ketamine therapy elsewhere, ask who prescribes, who watches the dose, and whether the dose has crept up. Bring one case to your next team meeting and decide who owns the follow-up call.

If a client is in ketamine therapy elsewhere, ask who prescribes, who watches the dose, and whether the dose has crept up.

If you are the person taking it, the same two questions work from the inside. Who is watching the dose? Has it crept up? Needing more is not weakness. It is information.

The people in that Manchester ward did not set out to end up there. Most of them started at 18 chasing the same thing a depressed adult chases in a clinic chair: a few hours where the noise stops. The drug is not the villain and it is not the cure. The question that decides which one it becomes is who is in the room when you take it, and whether anyone will still be there when it wears off.